Trial · NCT02299349
Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection
NCT02299349, Not applicable, Completed, TriHealth Inc.; results first posted 2015-04-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection. Trials, record NCT02299349. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02299349
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection
- NCT number
- NCT02299349
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 70 participants, actual
- Lead sponsor
- TriHealth Inc.
- Conditions
- Total Knee Arthroplasty
- Interventions
- bupivacaine liposome suspension, concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL
- First posted
- 2014-11-24
- Last updated
- 2018-10-09
- Results first posted
- 2015-04-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Scores (Visual Analog Pain Scores) | 1 day following surgery | visual analog pain scores (scale 0=no pain; 10=worst pain imaginable) |
| Secondary | MS04 Equivalent Consumption | 1 day following surgery | in hospital total MS04 equivalent consumption |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Scores (Visual Analog Pain Scores) | 1 day following surgery | units on a scale | MEAN | |
| SECONDARY | MS04 Equivalent Consumption | 1 day following surgery | mg | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Scores (Visual Analog Pain Scores) | Bupivacaine Liposome Suspension | 2.6 | Standard Deviation 1.27 | units on a scale | |
| Pain Scores (Visual Analog Pain Scores) | Concentrated Multi Drug Injection | 3.3 | Standard Deviation 1.55 | units on a scale | |
| MS04 Equivalent Consumption | Bupivacaine Liposome Suspension | 10.0 | Inter-Quartile Range 5.0 to 15.0 | mg | |
| MS04 Equivalent Consumption | Concentrated Multi Drug Injection | 15.0 | Inter-Quartile Range 8.0 to 20.0 | mg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bupivacaine Liposome Suspension | 35 | |
| Overall Study | STARTED | Concentrated Multi Drug Injection | 35 | |
| Overall Study | COMPLETED | Bupivacaine Liposome Suspension | 35 | |
| Overall Study | COMPLETED | Concentrated Multi Drug Injection | 35 | |
| Overall Study | NOT COMPLETED | Bupivacaine Liposome Suspension | 0 | |
| Overall Study | NOT COMPLETED | Concentrated Multi Drug Injection | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bupivacaine Liposome Suspension | ||
| Total, all-cause mortality | Concentrated Multi Drug Injection | ||
| Total, other adverse events | Bupivacaine Liposome Suspension | 0 | 35 |
| Total, other adverse events | Concentrated Multi Drug Injection | 0 | 35 |
| Total, serious adverse events | Bupivacaine Liposome Suspension | 0 | 35 |
| Total, serious adverse events | Concentrated Multi Drug Injection | 0 | 35 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bupivacaine Liposome Suspension vs Concentrated Multi Drug Injection: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02299349
GET https://conductscience.org/api/trials/v1/NCT02299349/registered